"The acquisition of Epidauros also brings to us the assets, know-how, and staff for which Epidauros is so well-respected. In particular, Epidauros will provide Clinical Data with additional scientific expertise, biotechnology partnering capabilities and a deep understanding of European clinical markets. Epidauros has grown its pharmacogenetic services business in support of the pharmaceutical and biotechnology industries and earned a reputation for excellence throughout Europe and the US. We expect the capabilities of Epidauros' laboratories to complement those of Clinical Data and to contribute a strong local presence in the important German market. With our operations in the UK and France, this transaction provides Clinical Data with laboratories in three top European markets."
To further advance the combined abilities of the two companies and to
expand Clinical Data's clinical testing and targeted therapeutics programs,
Michael Lutz, Ph.D., the current CEO of Epidauros, has agreed to join
PGxHealth as the Senior Vice President of Pharmacogenetic Partnerships. Dr.
Lutz commented, "We welcome the opportunity to become a part of Clinical
Data and are excited to join forces and work toward building the world's
leading pharmacogenetic enterprise. At Epidauros, we are proud of our
history of innovation and our track record with respect to providing
pharmacogenetic solutions to many partners. We can now further leverage
Epidauros' and Cogenics' support of pharmaceutical trials with our leading
pharmaceutical clients. Together, the companies have supported more than
1,000 clinical trials over the past several years. Moreover, the
combination of Clinical Data's an
|SOURCE Clinical Data, Inc.|
Copyright©2007 PR Newswire.
All rights reserved